Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

Trial Profile

Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Pegfilgrastim
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrails.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top